Merus N.V. Aktie News

TAMPERE, Finland, July 03, 2025 (GLOBE NEWSWIRE) -- The energy storage facility delivered by Merus Power to Lappeenranta, Finland, has been completed and put into market use on 15 May 2025. The energy storage facility is owned by a joint venture between Ardian's Clean Energy Evergreen Fund and the local energy provider Lappeenrannan Energia. It is one of the largest energy storage facilities in...

MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rat...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a p...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

Merus stock rocketed — and hammered Bicara — after unveiling promising new results for its experimental head-and-neck cancer treatment.

-  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V.